Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCT1100 in Primary Ciliary Dyskinesia with DNAI1 mutations
NCT06600425Phase 1Completed
- Sponsor
- ReCode Therapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RCT1100 in primary ciliary dyskinesia (PCD), sponsored by ReCode Therapeutics. Primary endpoints: Adverse Events at 24 weeks, Treatment-Emergent Adverse Events at 24 weeks and 1 more. Started Sep 2024; status: completed.
02
Drugs
RCT1100
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on NCT06600425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600425.